Y. Ohe

591 total citations
21 papers, 414 citations indexed

About

Y. Ohe is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Y. Ohe has authored 21 papers receiving a total of 414 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Y. Ohe's work include Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Research Studies (9 papers) and Cancer therapeutics and mechanisms (5 papers). Y. Ohe is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Research Studies (9 papers) and Cancer therapeutics and mechanisms (5 papers). Y. Ohe collaborates with scholars based in Japan, United States and France. Y. Ohe's co-authors include Hironobu Ohmatsu, Nagahiro Saijo, Seiji Niho, Tetsu Shinkai, Akira Kojima, Tomoki Tamura, Hiroshi Kunikane, Hiroaki Okamoto, Fumihiko Kanzawa and Katsumi Eguchi and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Y. Ohe

20 papers receiving 400 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Y. Ohe Japan	10	245	161	103	89	63	21	414
Nanya Wang China	13	148 0.6×	150 0.9×	79 0.8×	48 0.5×	30 0.5×	29	450
D. Mignard France	7	289 1.2×	216 1.3×	92 0.9×	43 0.5×	33 0.5×	10	442
Fadel Bennani Ireland	7	144 0.6×	96 0.6×	69 0.7×	26 0.3×	48 0.8×	20	398
Linda D. Compton United States	5	260 1.1×	224 1.4×	49 0.5×	54 0.6×	16 0.3×	12	490
Levin Thomas India	10	101 0.4×	153 1.0×	55 0.5×	29 0.3×	54 0.9×	30	364
Ming-Shyan Huang Taiwan	9	113 0.5×	164 1.0×	84 0.8×	57 0.6×	26 0.4×	19	428
Nitika Sharma United States	9	277 1.1×	109 0.7×	164 1.6×	31 0.3×	16 0.3×	18	488
Jiang Wang China	10	107 0.4×	121 0.8×	55 0.5×	25 0.3×	17 0.3×	46	425
Jonathan Evans United Kingdom	7	156 0.6×	109 0.7×	47 0.5×	81 0.9×	72 1.1×	12	355
Han Zhu China	12	80 0.3×	175 1.1×	29 0.3×	40 0.4×	46 0.7×	29	386

Countries citing papers authored by Y. Ohe

Since Specialization

Citations

This map shows the geographic impact of Y. Ohe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Y. Ohe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Y. Ohe more than expected).

Fields of papers citing papers by Y. Ohe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Y. Ohe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Y. Ohe. The network helps show where Y. Ohe may publish in the future.

Co-authorship network of co-authors of Y. Ohe

This figure shows the co-authorship network connecting the top 25 collaborators of Y. Ohe. A scholar is included among the top collaborators of Y. Ohe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Y. Ohe. Y. Ohe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hann, Christine L., Ying Cheng, David R. Spigel, et al.. (2025). Abstract CT094: Durvalumab (D) vs placebo (P) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC): Outcomes by PD-L1 expression in ADRIATIC. Cancer Research. 85(8_Supplement_2). CT094–CT094.

Okuma, Yusuke, et al.. (2022). 1635P Impact of treatment sequence on clinical outcomes in patients with thymic carcinoma. Annals of Oncology. 33. S1289–S1289. 1 indexed citations

Kawazoe, Hitoshi, Ryuji Uozumi, Hiroki Hashimoto, et al.. (2021). Effect of renin-angiotensin system inhibitors on pemetrexed plus platinum-induced hematological toxicities: a multicenter retrospective study using three propensity score analyses.. PubMed. 76(6). 266–271. 1 indexed citations

Itahashi, Kota, Shintaro Kanda, Yuki Fujiwara, et al.. (2017). Dried plasma spot assay for sunitinib and its active metabolite by high performance liquid chromatography tandem mass spectrometry. Annals of Oncology. 28. x171–x171. 1 indexed citations

Aikawa, Hiroaki, Kota Itahashi, Shintaro Kanda, et al.. (2015). 449P Distribution of erlotinib to brain, tumor lesion and normal tissue analyzed by matrix assisted laser desorption/ionization mass spectrometry imaging and liquid chromatography-tandem mass spectrometry. Annals of Oncology. 26. ix125–ix125. 3 indexed citations

Yoshida, Teruhiko, Seiji Niho, Keiko Goto, et al.. (2014). Protective Effect of Magnesium Preloading on Cisplatin-induced Nephrotoxicity: A Retrospective Study. Japanese Journal of Clinical Oncology. 44(4). 346–354. 62 indexed citations

Morise, Masahiro, Seiji Niho, Shingo Matsumoto, et al.. (2014). Low-dose Irinotecan as a Second-line Chemotherapy for Recurrent Small Cell Lung Cancer. Japanese Journal of Clinical Oncology. 44(9). 846–851. 16 indexed citations

Tsukada, Hiroko, Akira Yokoyama, Kōichi Goto, et al.. (2014). Randomized controlled trial comparing docetaxel-cisplatin combination with weekly docetaxel alone in elderly patients with advanced non-small-cell lung cancer: Japan Clinical Oncology Group (JCOG) 0207. Japanese Journal of Clinical Oncology. 45(1). 88–95. 22 indexed citations

Planchard, David, Paul A. Dickinson, Kathryn H. Brown, et al.. (2014). Preliminary Azd9291 Western and Asian Clinical Pharmacokinetics (Pk) in Patients (Pts) and Healthy Volunteers (Hv): Implications for Formulation, Dose and Dosing Frequency in Pivotal Clinical Studies. Annals of Oncology. 25. iv154–iv154. 3 indexed citations

10.

Makino, Yoshinori, Nobuyuki Yamamoto, Ikuo Sekine, et al.. (2012). Gender Difference in Hematological Toxicity Among Lung Cancer Patients Receiving Amrubicin Monotherapy. Japanese Journal of Clinical Oncology. 42(12). 1187–1191. 5 indexed citations

11.

Ogawa, Tadashi, et al.. (2012). Simultaneous Detection of Multicytotoxic Drugs on Occupational Environment by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Analysis. Annals of Oncology. 23. xi164–xi165. 2 indexed citations

12.

Abe, Takashige, Akira Yokoyama, Koji Takeda, et al.. (2011). Randomized phase III trial comparing weekly docetaxel (D)-cisplatin (P) combination with triweekly D alone in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): An intergroup trial of JCOG0803/WJOG4307L.. Journal of Clinical Oncology. 29(15_suppl). 7509–7509. 29 indexed citations

13.

Niho, Seiji, Koichi Kubota, Kōichi Goto, et al.. (2010). Survival improvement in patients (pts) with small cell lung cancer (SCLC): A historical comparison before and after amrubicin (AMR) approval in Japan.. Journal of Clinical Oncology. 28(15_suppl). e18105–e18105. 2 indexed citations

14.

Ohe, Y.. (2001). Phase I Studies of Cisplatin and Docetaxel Administered by Three Consecutive Weekly Infusions for Advanced Non-small Cell Lung Cancer in Elderly and Non-elderly Patients. Japanese Journal of Clinical Oncology. 31(3). 100–106. 18 indexed citations

15.

Niho, Seiji, Y Nishiwaki, Hironobu Ohmatsu, et al.. (2000). Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen. Lung Cancer. 27(3). 159–167. 60 indexed citations

16.

Sekine, Ikuo, Yutaka Nishiwaki, Ryutaro Kakinuma, et al.. (2000). Dose intensity of irinotecan (CPT) combined with weekly cisplatin (DDP) and etoposide (ETOP) in patients (pts) with metastatic lung cancer (LC): Phase I/II study JCOG 9507. Lung Cancer. 29(1). 38–38. 5 indexed citations

17.

Ohe, Y., Dongyan Zhao, Nagahiro Saijo, & Eckhard R. Podack. (1995). Construction of a Novel Bovine Papillomavirus Vector Without Detectable Transforming Activity Suitable for Gene Transfer. Human Gene Therapy. 6(3). 325–333. 32 indexed citations

18.

Oshita, Fumihiro, Naoki Yamamoto, Y. Ohe, et al.. (1995). Intensive Chemotherapy with Cisplatin, Doxorubicin, Cyclophosphamide, Etoposide and Granulocyte Colony-stimulating Factor for Advanced Thymona or Thymic Cancer: Preliminary Results. Japanese Journal of Clinical Oncology. 25(5). 208–12. 21 indexed citations

19.

Kojima, Akira, Yoshifumi Soejima, Hiroaki Okamoto, et al.. (1994). A Randomized Prospective Study of Imipenem-Cilastatin With or Without Amikacin as an Empirical Antibiotic Treatment for Febrile Neutropenic Patients. American Journal of Clinical Oncology. 17(5). 400–404. 20 indexed citations

20.

Ohe, Y., Yusuke Sasaki, Tetsu Shinkai, et al.. (1992). Phase I Study and Pharmacokinetics of CPT-11 With 5-Day Continuous Infusion. JNCI Journal of the National Cancer Institute. 84(12). 972–974. 110 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact